Tele: 561.316.3330
Breaking Medical Device News

Monday, October 18, 2021
HomeMicroPort Orthopedics Inc.MicroPort Orthopedics Inc. Announces Launch of its EVOLUTION® Revision Tibial System and...

MicroPort Orthopedics Inc. Announces Launch of its EVOLUTION® Revision Tibial System and EVOLUTION® BioFoam® Tibia

April 5, 2017

MicroPort Orthopedics Inc., a medical device company that develops and manufactures cutting edge joint replacement implants designed to help patients achieve full function faster, announced the launch of the EVOLUTION® Revision Tibial System and EVOLUTION® BioFoam® Tibia.

MicroPort Orthopedics continues to grow its product portfolio with a steady cadence of product launches,” said Aurelio Sahagun, President, MicroPort Orthopedics. “These product launches demonstrate our commitment to help improve patient outcomes by giving surgeons a broad array of choices that allow them to treat their patients. We are excited to bring the benefits of the Medial-Pivot design to a revision system.”

The Evolution Medial-Pivot Knee System is built on 17 years of clinical success1 and addresses key issues that can improve satisfaction for patients undergoing total knee replacement. The EVOLUTION® Revision Tibial System is designed to offer surgeons intra-operative flexibility to meet individual anatomic patient needs, address fixation issues caused by poor bone stock, while maintaining the proven kinematic benefits of the Medial-Pivot design. The new system was designed by expert surgeons from Europe, Asia, Canada, and the United States and features all the benefits of the EVOLUTION® Medial-Pivot design.

In addition to its EVOLUTION® Revision Tibial System, MicroPort Orthopedics also announced the launch of its EVOLUTION® BioFoam® Tibia. This launch completes the EVOLUTION® Medial-Pivot Cementless System, which consists of the EVOLUTION® porous femoral component and the new EVOLUTION® BioFoam® tibial component. This system is designed to combine the unrivaled benefits of the Medial-Pivot philosophy with the advantages of early fixation without compromising the long-term demands that are required in today’s increasingly young and more active patients.2 Building on the success of the ADVANCE® BioFoam® Tibia, which reported survivorship of 98% at two years3, the EVOLUTION® BioFoam® Tibia will further enhance the product portfolio.

“I have used the MicroPort Orthopedics Medial-Pivot Knee System for three years,” said Dr. Brian de Beaubien, M.D., St. John’s Providence Park Hospital in Novi, MI. “The majority of my primary knees are cementless, and I do not use screws. In my experience with the ADVANCE® and now EVOLUTION®, BioFoam® has an excellent fixation. I have been following x-rays now for several years, and I don’t see any radiolucencies or sclerotic lines around the keel, that would suggest movement of the component. The BioFoam® Tibia combined with the unique design of the EVOLUTION® Medial-Pivot Knee is truly different from anything else. It is my go-to knee.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

Ganymed Robotics Awarded a €2.5M Grant from the EC through the EIC Accelerator Program

Ganymed Robotics is developing a radically new approach to surgical robotics by combining computer vision, a branch of artificial intelligence, and mechatronics.

Global Healthcare Exchange Announces Acquisition of Explorer Surgical

Explorer Surgical will operate as a wholly-owned subsidiary of GHX.

Arlington Scientific Broadens Product Portfolio and Further Expands its Product Offering Through the acquisition of Non-Mammalian Blocking Buffers

Arlington Scientific, Inc. (ASI) is pleased to announce that it has acquired the non-mammalian blocking buffer product line from Clark McDermith, former owner of...

Laborie Medical Technologies Acquires Pelvalon

Laborie was represented by Piper Sandler (financial advisor) and Simpson Thacher & Bartlett LLP (legal advisor). Pelvalon was represented by J.P. Morgan Securities LLC (financial advisor) and Dorsey & Whitney LLP (legal advisor).

Herculite Products, Inc. Promotes Two Employees to New Roles

Paul Flaherty Chief Strategy Officer and Marco Angelone is being promoted to the role of Chief Financial Officer.

Prof. Joseph Kvedar Added to the Sweetch Advisory Board Member

Prof. Josdeph Kvedar is the current chair of the board at the American Telemedicine Association (ATA), formerly VP of Connected Health at Mass-Gen Brigham, co-chair of the American Medical Association (AMA) Digital Medicine Payment Advisory Group, and author of The Internet of Healthy Things and The New Mobile Age.

Sid Bala Named President of HealthChampion

Sid Bala is the former president and chief executive officer of alligatortek, a custom software applications company that was acquired by HealthChampion in 2020 where he led them for 27 years after he founded the business

Cochlear Announces FDA Approval and Clearance of first-of-its-kind Remote Care Capabilities for Nucleus and Baha Systems

The FDA approval for the cochlear implant solution and FDA clearance for the Baha solution is the first step in commercializing the product offering, anticipated spring 2022, and complement Cochlear's existing Remote Care offerings.

By using this website you agree to accept Medical Device News Magazine Privacy Policy